Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or West Virginia for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to West Virginia only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. West Virginia (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Mayez El-harake (NPI 1578550679)

Field	Value
Entity Type	Individual
Organization	Mayez El-harake
Address	275 Dry Hill Rd
City	Beckley
State	WV
ZIP	25801
Taxonomy	Medical Oncology Physician
NPI Enumerated	October 4, 2005

Payer Source	Total Paid
Medicare	$1.1M
Medicaid	$0

Key Findings

This provider’s Medicare business is heavily centered on oncology infusion and immunotherapy: J9271 (pembrolizumab) alone accounts for $800.7K and 77.3% of the provider’s Medicare revenue, and procedural chemotherapy codes such as 96413 appear among the top revenue drivers. The presence of multiple infusion administration add‑ons (96417, 96415, 96411) plus G0498 for initiation/transition of pump‑based infusions supports the interpretation that this is an in‑office infusion practice delivering systemic cancer therapies. Imaging and lab entries (e.g., 74177 at $24.2K and 80053 at $5.7K) are present but represent much smaller revenue streams relative to drug and infusion administration.

Revenue concentration is very high: the precomputed top‑3 Medicare codes represent 85.8% of Medicare revenue, with J9271 alone representing 77.3% of that revenue. That level of concentration creates exposure to shifts in utilization or reimbursement of that single agent despite a small slate of additional chemo and supportive codes contributing the remainder of billings. Analysts should treat underlying volume trends for J9271 as the primary driver of this provider’s financial performance on Medicare.

Payer mix is effectively single‑payer Medicare: Lifetime Medicare revenue is $1.1M while there is no Medicaid billing on file. Because Medicaid activity is absent, the practice’s public‑payer exposure and risk profile should be evaluated almost entirely through its Medicare utilization patterns and reimbursement trends.

Competitive standing on the headline drug and chemo codes is modest rather than dominant. J9271 ranks #477 of 1841 providers nationally (74th percentile; typical, unremarkable volume for this code), Q5108 ranks #27 of 125 (79th percentile; typical, unremarkable volume for this code), and 96413 ranks #864 of 7514 (88th percentile; typical, unremarkable volume for this code), indicating routine community oncology volumes rather than leadership positions in national markets. These ranks imply the provider participates meaningfully in standard oncology regimens but is not a high‑volume national hub for these therapies.

Several codes are statistical outliers or unusually concentrated at the procedure level and may reflect operational practices tied to infusion throughput. 96523 (irrigation of venous access devices) is an extreme outlier (rank #16 of 1643, 99th percentile; extreme outlier, far above typical national volume for this code), while 96372 (therapeutic/subcutaneous injections) is at the 97th percentile (notably above typical national volume for this code). The combination of very high venous access device activity and above‑typical injection volumes is consistent with a busy infusion clinic model that performs frequent line maintenance and supportive injections.

Code mix indicates adoption of contemporary supportive care and biosimilar products alongside high‑cost immunotherapy: Q5108 (pegfilgrastim‑jmdb, fulphila) contributes $46.5K (4.5% of Medicare revenue) and appears high in rank among peers, signaling use of biosimilar growth‑factor support in patients receiving cytotoxic or immunotherapy. That, together with routine use of antiemetic J2469 and multiple infusion administration codes, paints a picture of an oncology practice delivering multimodal systemic therapy and associated supportive care services.

Although the practice bills for evaluation/management visits and diagnostics, these are small relative to drug revenue and support an infusion‑centric business model. Examples include 99214 at $11.5K (1.1% of Medicare revenue) and 74177 imaging at $24.2K (2.3% of Medicare revenue), showing E/M and diagnostic services supplement—but do not substitute for—the large oncology drug revenue stream. For payers and network planners, that implies facility and drug‑cost considerations will dominate contracting discussions.

This provider is long‑tenured in Medicare data, with an NPI enumerated on 2005-10-04 (~21 years ago), indicating an established practice history. Tenure combined with the concentrated drug mix suggests stability in practice operations but also emphasizes the importance of monitoring utilization and reimbursement trends for J9271 and related infusion services as the primary indicators of future Medicare revenue performance.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

69 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	18,620	$40	$800.7K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	530	$90	$46.5K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	460	$90	$41.9K
74177	The provider performs computed tomography of the abdomen and pelvis with contrast material to diagnose the cause of abdominal or pelvic pain or other abnormalities of the internal organs.	160	$150	$24.2K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	130	$90	$11.5K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	80	$130	$11K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community…	50	$180	$9.2K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	150	$60	$8.7K
36415	In this procedure, the provider inserts a needle into a vein to collect a blood sample.	1,020	$10	$8.1K
71260	In this diagnostic procedure, the provider performs a computed tomography, or CT, examination of the thorax using contrast material.	170	$50	$7.8K

Showing 1–10 of 69

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 69 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. West Virginia Distribution

Mayez El-harake — 3 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — West Virginia

Full comparison — all codes billed, vs. state median

69 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	2	10	21,430	$40	$920.6K
Q5108	2	10	580	$90	$52.3K
96413	2	10	170	$90	$19.5K
J9217	5	10	100	$130	$15.9K
Q0138	2	10	34,680	$1	$13.4K
99214	1,127	2,740	100	$70	$11.8K
G0498	2	10	60	$180	$10.9K
77067	88	120	160	$40	$10.1K
74177	62	130	150	$60	$10K
74176	115	130	110	$60	$7.5K

Showing 1–10 of 69

Related Providers

Other providers that share a Tax Identification Number (TIN) with Mayez El-harake, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Charleston Area Medical Center Inc	WV	General Acute Care Hospital	$0	$200.1M
Charleston Area Medical Center, Inc.	WV	General Acute Care Hospital	$0	$50.9M
Columbus Radiology Corp	OH	Diagnostic Radiology Physician	$0	$49.9M
Somc Medical Care Foundation, Inc.	OH	Family Medicine Physician	$0	$25.3M
Rainelle Medical Center Inc	WV	Federally Qualified Health Center (FQHC)	$0	$14.3M
Mark Le	FL	Diagnostic Radiology Physician	$10.7M	$0
Beckley Oncology Associates Inc	WV	Radiation Oncology Clinic/Center	$0	$5M
Rajiv Khanna	WV	Medical Oncology Physician	$2M	$0
Charleston Area Medical Center, Inc.	WV	Hospitalist Physician	$0	$1.4M
Linda Armstrong	GA	Diagnostic Radiology Physician	$643.9K	$175.1K

Nearby Providers

Other providers in the same ZIP code as Mayez El-harake, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Raleigh General Hospital LLC	WV	General Acute Care Hospital	$0	$36.4M
Community Health Systems, Inc.	WV	Federally Qualified Health Center (FQHC)	$0	$35M
Fmrs Health Systems Inc	WV	Community/Behavioral Health Agency	$0	$27M
Health Care Alliance, Inc.	WV	Emergency Medicine Physician	$0	$25M
Jan-care Ambulance Of Raleigh County Inc	WV	Land Ambulance	$1.9M	$20.8M
Appalachian Regional Healthcare, Inc	WV	General Acute Care Hospital	$0	$18.3M
Raleigh County Commission On Aging, Inc.	WV	Home Health Agency	$0	$16.7M
Mountain State Home Health Care Inc	WV	Nursing Care Agency	$0	$16.5M
Family Options Providers, LLC.	WV	Community/Behavioral Health Agency	$0	$16.1M
Raleigh County Commission On Aging, Inc.	WV	Home Health Agency	$0	$13.8M

Mayez El-harake — Billing Profile & Reimbursement Data

Sign up for Mayez El-harake — Billing Profile & Reimbursement Data policy alerts

Mayez El-harake — Billing Profile & Reimbursement Data

Sign up for Mayez El-harake — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References